SLC50A1 and Its Role in Liver Cancer
Author Information
Author(s): Wang Ganggang, Jin Wenzhi, Zhang Lianmei, Dong Meiyuan, Zhang Xin, Zhou Zhijie
Primary Institution: Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China
Hypothesis
This study aims to investigate the function and underlying mechanisms of SLC50A1 in the occurrence and progression of hepatocellular carcinoma (HCC).
Conclusion
The study identifies the METTL3/SLC50A1 axis as a novel therapeutic target in the context of hepatocellular carcinoma.
Supporting Evidence
- SLC50A1 is significantly upregulated in liver cancer compared to normal tissues.
- Overexpression of SLC50A1 predicts unfavorable prognosis in liver cancer patients.
- SLC50A1 enhances resistance of HCC cells to Doxorubicin (DOX) and 2-deoxy-D-glucose (2-DG).
- Downregulation of SLC50A1 inhibits liver cancer cell growth by inducing G1 cell cycle arrest.
- SLC50A1 regulates cellular glycolysis and the cell cycle, promoting tumorigenesis.
Takeaway
SLC50A1 is a protein that helps liver cancer cells grow and resist treatment, making it a potential target for new therapies.
Methodology
The study utilized bioinformatics analysis, clinical sample testing, in vitro and in vivo experiments to assess SLC50A1 expression and its effects on HCC.
Participant Demographics
15 HCC patients with clinical samples collected.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website